SEPTEMBER 9, 2022: Gaudenzia has released its second annual FrontLine Report for fiscal year 2022. The report provides county-by-county data and observations on substance use trends in the areas we serve throughout Pennsylvania, Delaware, and Maryland.
Earlier today, Gaudenzia President & CEO Dr. Dale Klatzker hosted a Zoom news conference and panel discussion on report findings. Panelists included the following senior public policy leaders from each region represented in the data:
- Dr. Bethany Hall-Long, Delaware Lieutenant Governor
- Secretary Jen Smith, PA Department of Drug and Alcohol Programs
- Dr. Jean Moise, Washington D.C. Department of Behavioral Health Deputy Director
- Honorable Ronald A. Silkworth, Anne Arundel County Circuit Judge
View the full news conference and panel discussion below:
Trends in Substance Use: Key Takeaways
While our FY-22 FrontLine Report provides data at the county level, the overall summary data collected informs the following key takeaways:
- Gaudenzia’s licensed SUD treatment programs served a total of 13,387 clients during FY-22.
- Our treatment programs served a greater number of clients who identified as male (66%) than clients who identified as female (34%).
- Approximately 30% of admissions had a secondary SUD diagnosis, with most reporting stimulant use.
- Opioid use declined by 9% from 2021 to 2022, while alcohol use increased by 1%.
- Stimulant use disorder remained the most prevalent primary diagnosis for women admitted into treatment, with a 3% increase from 2021.
About Our FrontLine Report Data
Our 2022 FrontLine Report data was collected from diagnosis forms within our electronic health record system from FY-22. This data excludes clients served in Gaudenzia’s affordable housing programs and some of those served in programs that have since closed. Data in this report does not include programs we oversee in Washington D.C. at RAP, Inc., as they are not yet a part of our electronic health records system.
Future iterations of Gaudenzia’s annual FrontLine Report will pull data from clinician-obtained biopsychosocial questionnaires to ensure accurate and more in-depth reporting. Our vision is to provide a robust data resource to help inform and educate policymakers, members of the media, and local community members. The data represented in our FrontLine Report also helps guide treatment decisions within our own organization, as it allow us to track emerging treatment needs and adapt our services accordingly.
If you or a loved one needs help with substance use or co-occurring disorders, please call our 24-hour Treatment and Referral HelpLine at 833.976.HELP (4357).